BioCentury
ARTICLE | Clinical News

Eight-week data for Merck's triple HCV combo

October 21, 2015 12:57 AM UTC

An abstract released ahead of next month's American Association for the Study of Liver Diseases (AASLD) meeting describes Phase II findings across multiple HCV genotypes produced by eight weeks of treatment with a once-daily regimen of three oral antivirals from Merck & Co. Inc. (NYSE:MRK).

Pooled results from the C-CREST-1 and 2 studies showed grazoprevir ( MK-5172), MK-3682 and either elbasvir ( MK-8742) or MK-8408 produced an SVR12 in 98% of HCV genotype 1 patients. In genotype 2 patients, the best performing triple combination produced an SVR12 in 94% of patients while the SVR12 rate for other doses was 64%. In genotype 3 patients, the SVR12 rate was 91%. ...